Alivus Life Sciences will host an in-person investor and analyst meeting on August 12, 2026, in Mumbai. The engagement is scheduled as part of the Emkay Confluence conference and aims to provide stakeholders with direct access to company representatives through both group sessions and one-on-one discussions. This interaction offers investors a platform to discuss the company’s strategic direction and operational updates directly with management.

The disclosure was made pursuant to Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 7, 2026, regarding the upcoming event. Rudalf Corriea, Company Secretary and Compliance Officer, signed the intimation letter addressed to the Department of Corporate Services at BSE and the Listing Manager at NSE.

The meeting details are structured to facilitate comprehensive dialogue between the company and its investors. The format includes a mix of group interactions and individual meetings, allowing for broader dissemination of information as well as tailored responses to specific investor queries. The event takes place at the Emkay Confluence conference venue in Mumbai.

The company noted that the schedule and mode of the meeting may undergo changes due to exigencies on the part of the investor, analyst, or the company itself. Investors are advised to monitor official communications for any last-minute updates regarding the timing or format of the sessions.

What This Means for Investors

The scheduled meet provides a timely opportunity for market participants to engage with Alivus Life Sciences’ leadership team. As the company continues to operate under its new identity following its rebranding from Glenmark Life Sciences Limited, such direct engagements help reinforce transparency and clarity regarding its business trajectory. The inclusion of one-on-one sessions suggests a focus on addressing specific concerns or investment theses held by institutional and high-net-worth investors attending the Emkay Confluence.

Alivus Life Sciences Limited reported a net profit of ₹160 crore for the quarter ended June 30, 2026, supported by robust revenue growth and expanding margins. The company’s revenue from operations stood at ₹640 crore, marking a 6.4% year-on-year increase, while EBITDA reached ₹234 crore, up 29.1% year-on-year. This financial performance underscores the resilience of its diversified portfolio, particularly as the non-GPL segment delivered strong growth that counterbalanced significant headwinds in the GPL business.

The earnings call, held on July 31, 2026, highlighted a sharp divergence in business segments. While the GPL business declined by 52.6% year-on-year due to inventory rationalization, the non-GPL business surged by 26.5% year-on-year, driven by successful new product launches and strong demand across geographies. Management emphasized that this diversification has strengthened the revenue base, creating a platform for sustainable growth despite near-term volatility in specific segments.

Financial Performance Highlights

Gross margins improved to 60.2%, an increase of 510 basis points year-on-year, attributed to a favorable product mix, new launches, and operational efficiencies. EBITDA margins expanded by 650 basis points to 36.6%, further boosted by forex gains. Chronic therapies anchored the top line, accounting for 74% of revenue, with CVS and CNS contributing 58% collectively.

Operational Updates and Guidance

Dr. Yasir Rawjee, Managing Director and CEO, noted that while GPL growth is expected to remain flattish in FY '27, the business is historically weighted towards the second half, suggesting a stronger H2 performance. The CDMO business recorded 3.8% year-on-year growth, with management expecting momentum to build in the second half from newly added projects. Two new CDMO contracts are expected to close in early H2 FY '27.

On the capital expenditure front, Solapur Phase 1 is progressing with a slight delay but is expected to be operational in early Q3 FY '27. Construction at the Talaja R&D center has begun in earnest. The company incurred capex of ₹85 crore in the quarter and expects total capex of approximately ₹540 crore for FY '27. Alivus remains debt-free, with cash and cash equivalents including short-term investments totaling ₹880 crore as of June 30, 2026.

What the Numbers Show

The expansion in EBITDA margins to 36.6% significantly outpaces the 6.4% revenue growth, indicating a strong operating leverage effect from new high-margin launches and process improvements. However, management cautioned that raw material price increases, partly linked to geopolitical tensions, pose a risk to sustaining these peak margins. Consequently, the FY '27 EBITDA margin guidance is conservatively set at 30% to 32%, although management indicated potential for up to 34% if steady-state conditions prevail. This suggests that while current profitability is robust, future margin stability will depend on the company’s ability to pass on cost increases to customers amidst volatile input prices.

R&D expenditure stood at ₹24 crore, or 3.7% of sales, with management targeting a steady-state spend of around 4%. The pipeline remains robust with 617 DMF and CEP filings globally. The high-potent API portfolio includes 29 products in the active grid, addressing a total addressable market of $82 billion, with commercialization expected to gain traction from FY '28 onwards.